Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 5 of 23
Aug 3, 2026As news spreads of one individual receiving special access to Eli Lilly’s promising obesity candidate, retatrutide, medical professionals and patient advocates are calling for clarity around the company’s criteria, processes, and communications. This feature examines the implications for clinical practice, drug development, and equitable access.
Sophia Reynolds
Aug 1, 2026This comprehensive analysis explores a month filled with major executive hires, departures, and notable layoffs across the biopharmaceutical sector and healthcare organizations. The evolving leadership landscape, coupled with workforce reductions at prominent companies, highlights the shifting priorities and pressures in the healthcare industry’s ongoing transformation.
Dr. Priya Nandakumar
Jul 31, 2026Alnylam's recently announced revenue guidance reduction for its TTR franchise has resulted in dramatic market repercussions. Observers question the company's sales trajectory and its competitive positioning amid broader industry volatility.
Dr. Priya Nandakumar
Jul 30, 2026Bristol Myers Squibb (BMS) has reported exceptionally strong quarterly financial results, prompting an upward revision of its 2026 outlook. However, these achievements face significant headwinds due to further delays in pivotal clinical data for Cobenfy, the company’s high-profile Alzheimer’s candidate, and a rescheduled readout for the cardiovascular drug milvexian. As BMS navigates these developments, industry observers are debating how execution risks and shifting clinical timelines might impact its market trajectory and R&D pipeline resilience.
Michael Torres
Jul 30, 2026Regeneron has faced mounting pressure from investors and industry watchers to engage more actively in mergers and acquisitions (M&A), following an exceptionally strong second quarter that has built an $18 billion war chest. However, the company’s reticence to pursue major deals is attracting renewed scrutiny amid recent clinical setbacks, raising questions about its long-term growth strategy in a rapidly consolidating industry.
Dr. Alex Morgan
Jul 30, 2026Johnson & Johnson has intensified its position in the competitive cell therapy arena by striking a multifaceted partnership with Sail Biomedicines, granting J&J the exclusive right to acquire the biotech for up to $925 million and offering an avenue for further payments exceeding $2.58 billion. The agreement could signal a new wave of strategic investments in the CAR T cell therapy sector.
Sophia Reynolds
Jul 28, 2026As GSK reports substantial impairment charges for the second quarter, the UK-based pharma giant launches a sweeping cost-savings initiative designed to offset losses and safeguard future profitability. The company's new CEO seeks to balance cost reductions with investments in drugs approaching late-stage trials.
Dr. Priya Nandakumar
Jul 27, 2026Prescription drug spending has come under renewed attention as industry and regulatory changes—including updates to the No Surprises Act and surging arbitration costs—impact patients, providers, and payers. This analytical deep dive explores the key factors shaping the current drug cost debate, highlighting the pressures driving policy interventions and the ongoing challenge of balancing innovation, access, and affordability.
Emily Carter
Jul 27, 2026The acquisition of Forte Biosciences by Argenx marks a strategic expansion of Argenx’s immunology expertise. Forte’s FB102, an investigational antibody showing promise in multiple autoimmune indications, positions Argenx for future growth in therapeutic innovation.
Sophia Reynolds
Jul 26, 2026A significant partnership emerges in employer-sponsored health benefits as Priority Health teams up with Color Health and Grail to deliver enhanced cancer navigation and diagnostic solutions. The collaboration is poised to offer comprehensive virtual support and advanced early detection technology to self-funded employers, reshaping the future of workplace cancer care.
Emily Carter
Jul 25, 2026Sanofi's ambitious $1.4 billion acquisition of Kymab was expected to reinforce its portfolio in anticipation of the Dupixent patent cliff. However, another Kymab-developed therapy has failed clinical expectations for atopic dermatitis, renewing concerns over the success of recent M&A moves and raising critical questions about the future of Sanofi's immunology strategy.
Dr. Alex Morgan
Jul 23, 2026A growing number of Americans living with diabetes face uncertainty as the widely-used Lantus Solostar insulin pen appears increasingly difficult to obtain. This development comes in the wake of other insulin pens leaving the market, squeezing supply and raising questions about access, manufacturing resilience, and the impact on patient care. As advocates and policymakers watch closely, the situation underscores vulnerabilities within the medication supply chain for one of the world’s most essential drugs.
Michael TorresMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.